Authors:
EAP CB
GUENTERT TW
SCHAUBLINLOIDL M
STABL M
KOEB L
POWELL K
BAUMANN P
Citation: Cb. Eap et al., PLASMA-LEVELS OF THE ENANTIOMERS OF THIORIDAZINE, THIORIDAZINE 2-SULFOXIDE, THIORIDAZINE 2-SULFONE, AND THIORIDAZINE 5-SULFOXIDE IN POOR AND EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN AND MEPHENYTOIN, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 322-331
Authors:
MEYER UA
AMREIN R
BALANT LP
BERTILSSON L
EICHELBAUM M
GUENTERT TW
HENAUER S
JACKSON P
LAUX G
MIKKELSEN H
PECK C
POLLOCK BG
PRIEST R
SJOQVIST F
DELINISTULA A
Citation: Ua. Meyer et al., ANTIDEPRESSANTS AND DRUG-METABOLIZING-ENZYMES - EXPERT GROUP-REPORT, Acta psychiatrica Scandinavica, 93(2), 1996, pp. 71-79
Authors:
WALLNOFER A
GUENTERT TW
ECKERNAS SA
DINGEMANSE J
Citation: A. Wallnofer et al., MOCLOBEMIDE AND FLUVOXAMINE COADMINISTRATION - A PROSPECTIVE-STUDY INHEALTHY-VOLUNTEERS TO INVESTIGATE THE POTENTIAL DEVELOPMENT OF THE SEROTONIN SYNDROME, Human psychopharmacology, 10(1), 1995, pp. 25-31
Citation: M. Mayersohn et Tw. Guentert, CLINICAL PHARMACOKINETICS OF THE MONOAMINE OXIDASE-A INHIBITOR MOCLOBEMIDE, Clinical pharmacokinetics, 29(5), 1995, pp. 292-332
Authors:
GUENTERT TW
BANKEN L
HILTON S
HOLFORD NHG
Citation: Tw. Guentert et al., MOCLOBEMIDE - RELATIONSHIPS BETWEEN DOSE, DRUG CONCENTRATION IN PLASMA, AND OCCURRENCE OF ADVERSE EVENTS, Journal of clinical psychopharmacology, 15(4), 1995, pp. 84-94
Authors:
GRAM LF
GUENTERT TW
GRANGE S
VISTISEN K
BROSEN K
Citation: Lf. Gram et al., MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY, Clinical pharmacology and therapeutics, 57(6), 1995, pp. 670-677
Authors:
GUENTERT TW
GRANGE S
BOCK J
WALDBURGER R
BIRNBOECK H
HOFFMANNLAROCHE F
Citation: Tw. Guentert et al., LACK OF AN IMPORTANT INFLUENCE OF CYP2D6 OXIDATION STATUS ON THE PHARMACOKINETICS OF MOCLOBEMIDE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 151-151
Citation: Tw. Guentert et al., MIXED LINEAR AND NONLINEAR DISPOSITION OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B, British journal of clinical pharmacology, 37(6), 1994, pp. 545-551
Authors:
HOLFORD NHG
GUENTERT TW
DINGEMANSE J
KETTLER R
Citation: Nhg. Holford et al., PHARMACODYNAMICS OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B, British journal of clinical pharmacology, 37(6), 1994, pp. 553-557
Authors:
HOLFORD NHG
GUENTERT TW
DINGEMANSE J
BANKEN L
Citation: Nhg. Holford et al., MONOAMINE OXIDASE-A - PHARMACODYNAMICS IN HUMANS OF MOCLOBEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR, British journal of clinical pharmacology, 37(5), 1994, pp. 433-439
Citation: Tw. Guentert et al., REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 137-137
Citation: T. Stebler et Tw. Guentert, BIOAVAILABILITY OF INTRAMUSCULARLY ADMINISTERED TENOXICAM, Biopharmaceutics & drug disposition, 14(6), 1993, pp. 483-490